A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-11-05
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.